The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma.
Sylwia Popek-MarciniecWojciech StykMagdalena Wojcierowska-LitwinAneta Szudy-SzczyrekPaul DudekGrazyna Swiderska-KolaczJoanna Czerwik-MarcinkowskaSzymon ZmorzynskiPublished in: Journal of clinical medicine (2023)
(1) Background: Chemokines and chemokine receptors play an important role in tumor development. The aim of this study was to check the significance of CCL5 and CCR1 variants with response rate, survival, and the level of regulated on activation, normal T cells expressed and secreted (RANTES/CCL5) in multiple myeloma (MM) patients; (2) Methods: Genomic DNA from 101 newly diagnosed MM patients and 100 healthy blood donors were analyzed by Real-time PCR method (for CCL5 and CCR1 genotyping). In a subgroup of 70 MM patients, serum samples were collected to determine the level of RANTES; (3) Results: multivariate Cox regression showed increased risk of disease relapse or progression (HR = 4.77; p = 0.01) in MM patients with CG + CC genotypes of CCL5 rs2280788. In contrast, CT + TT genotypes of CCL5 rs2107538 were associated withdecreased risk of death (HR = 0.18; p = 0.028) and disease relapse or progression (HR = 0.26; p = 0.01). In MM patients with major genotypes of rs2280789, rs2280788, and rs2107538, higher survival rates were observed in response to treatment with thalidomide and bortezomib. Statistically significant lower RANTES levels were seen in minor genotypes and heterozygotes of CCL5 and CCR1 variants; (4) Conclusions: Major genotypes of CCL5 variants may be independent positive prognostic factors in MM.
Keyphrases
- newly diagnosed
- prognostic factors
- multiple myeloma
- liver fibrosis
- end stage renal disease
- copy number
- ejection fraction
- dendritic cells
- magnetic resonance
- magnetic resonance imaging
- regulatory t cells
- patient reported outcomes
- transcription factor
- randomized controlled trial
- free survival
- patient reported
- genome wide
- immune response
- high throughput
- smoking cessation
- cell free
- positron emission tomography
- placebo controlled
- phase iii